SCT is a curative approach using chemo-, radio-and immunotherapy for malignant and non-malignant hematological disorders. The European Group for Blood and Marrow Transplantation (EBMT) has been collecting yearly data on a survey basis since 1990. The variables within the survey are limited to detailed indications, number of patients, transplant type, stem cell source, type of conditioning regimen and donor type. The transplant rates in certain indications, patterns of stem cell source selection and donor availability and alternative donor use were analyzed in detail. The Turkish transplant registry data within EBMT-European Activity Survey (EBMT-EAS) were delivered by the EBMT Activity Survey Office. We compared the national data with the international EBMT-EAS data pool.
survey
In 2005 and 2006, 24 national centers responded to the European Group for Blood and Marrow Transplantation-European Activity Survey (EBMT-EAS). In 2005, the total activity in Turkey reached 600, and in 2006, exceeded 800. The ratio of auto-to allo-hematopoietic cell transplantation (allo-HCT) was 1:1, which was quite different in EBMT-EAS (2-2.5:1). Our population-based transplant rates for both allo-and auto-HCTs were 1-50 per 10 million inhabitants. The major indications for allo-HCT are acute leukemia (28%), chronic leukemia (22%) and non-malignant hematological problems (20%). There was a sharp drop in allo-transplants for CML (66%). In an autologous setting, the major indications were lymphoproliferative disorders (69%), solid tumors (16%) and leukemias. The graphical outlines for indications and their growing patency were nearly identical for both allo-and auto-HCTs. The use of PBSCs reached a ratio of 71%, which is the same in 2006 EBMT-EAS. For an autologous setting, the use of PBSCs is a standard approach (98%). The number of alternative donor transplants has risen in the last 2 years. The ratio of matched unrelated donor (MUD) and allo-cord blood HCT is 7% in 2006, which is quite different from the general 41% use of alternative donors in Europe.
The Turkish Transplant Registry (TTR) activity is in concordance with the indications in EBMT-EAS. The drop in allo-HCT for CML, the use of more PBSCs in allo-HCT and a rising tendency of allo-reduced intensity conditioning were concordant with the published EBMT-EAS. The only exception is the nearly equal number of allo-and autoHCTs. The transplant rates for allo-and auto-HCTs are quite low and at the lowest survey segment. The number of alternative donor transplants has risen within 3 years.
The total population in Turkey is reaching nearly 73 million. The median age of the total population is rather young in comparison with European countries. The growth rate is still high. The transplant centers are trying hard to transplant the in-country-referred patients. There are only a few patients transplanted from neighbor countries owing to this constraint.
The TTR (CIC 8405) was founded in 2001. Detailed information can be found at the EBMT web page in the national registries section. TTR is trying to convince the centers to submit their data to TTR, EBMT Registry Office or directly to the official online data entry and management system, ProMISE. The centers lack personnel, and the data management issue in many centers is delayed or hampered.
The number of transplant centers in Turkey is growing year by year. The total number of transplant centers has reached 30, of which 27 are also registered with EBMT. Many centers (90%) are performing both allo-and autoHCTs; a few centers are sole pediatric centers. The majority of pediatric centers are performing mostly allogeneic transplants. In the last 2 years (2005/2006), the approximate number of total transplants is above 800 per year, and the ratio of allo to auto is nearly the same (385/393) (Figure 1) . At the recent analysis of the EBMT-EAS, the transplant rate for both auto-and allo-HCTs in Turkey was in the 1-50 per 10 million inhabitant segment. This rate is far below when compared with developed European countries and the United States. Donor availability in Turkey is generous owing to the high number of siblings within families. In some cases, the physicians have to choose the best donor among several HLA-matched sibling candidates. Besides, the demand on alternative donor transplants is rising inevitably. The percentage of MUD and cord blood transplants within total allo-HCT activity has risen in the past 2 years (2005, 3% and 2006, 7%) ( Figure 2 ).
The majority of indications in allo-HCT are hematological malignancies. Between 1990 and 2005, the major indications for allo-HCT were acute leukemias (28%), CML (22%), non-malignant hematological problems (20%) and lymphoproliferative disorders (8%) (Figure 3 ). After the launch of imatinib in the markets and the paralyzing preliminary and latest results of the international randomized IFN vs STI571 study (IRIS) trial, the transplant rate for CML has dropped from 30% (1999) to 10% (2006), with a 66% reduction rate. According to EBMT-EAS data, the drop of CML transplant rate from 1999 to 2006 is approximately 23.7-6.1%, respectively. 2, 3 In an autologous setting, the major indications were lymphoproliferative disorders (myeloma and lymphoma, 69%) as expected, solid tumors (16%) and leukemias (14%) ( Figure 4 ). As clearly demonstrated in the figure, the transplant rate for lymphoproliferative disorders is rising continuously. This profile is in concordance with the reports of EBMT-EAS 2002. 4 The overall percentage of indications for both allo-and auto-HCTs and their yearly graphical attitude is in compliance with the most recent EBMT-EAS. 1 The most apparent disparity within the Turkish transplant kinetics and the EBMT-EAS is the ratio of auto-to allo-transplants. In nearly all of the reported activities so far, the ratio is 2-2.5:1. Interestingly, in our country, the ratio is always nearly the same, 1:1. This equivalence between allo-and auto-HCTs can be interpreted as a tendency for more allo-HCT or less auto-HCT within transplant centers. In both settings, the transplant rates are below the expected values.
Turkish Transplant Registry does not have detailed data about post transplant early and late complications. According to the publications so far, the incidence of GVHD is in concordance with international registry data. The rise in reduced intensity conditioning in the last 5 years has reduced the regimen-related toxicity ( Figure 5 ). At the 2001 EBMT-EAS, 27% of allo-HCTs were reported as reduced intensity conditioning; 5 in 2005, this ratio reached the value of 34%. Our recent analysis showed 23% use of reduced intensity conditioning in allo-HCT.
The growing use of more PBSCs in allo-HCT setting is also remarkable in Turkey (Figure 6 ). In 2003, EBMT-EAS reported 65% use of PBSCs for allo-HCT as a stem cell source. 6 According to pre-published 2006 EBMT-EAS results, the use of PBSCs at total allo-HCTs had reached 71%. 2 In 2006, the ratio was exactly the same for Turkey (276/385). Almost all autologous transplants were performed with PBSCs (98%), also in concordance with the survey.
In our country, nearly all the recipient-donor pairs are seropositive for CMV, EBV, Parvovirus B19 and hepatitis A virus (HAV). In our center, we are actively immunizing every hepatitis B virus (HBV)-naive donor/recipient for HBV. Mycobacterial infections are not common in transplant recipients, and we are not forcing centers to routinely use prophylaxis in Bacille Calmette Guerin (BCG) positive recipients. The approximate cost of transplantation is a very debatable issue in our country. Very recently, the health authority and social security service decided to reimburse the transplant costs in a cost-package model as a whole. In the former system, fee for service translated to auto-HCT costs of $ 20 000-25 000 and allo-HCT (HLA-matched sibling) of $ 50 000-75 000.
The government is going to pay, for all the allo-HCT, $ 50 000 per patient including all the medications, preparations, HLA confirmation, conditioning and post transplant follow-up to day þ 60, and for auto-HCT and high-dose chemotherapy, $ 35 000. This reimbursement policy is not realistic and reasonable for a country such as Turkey, which is capable of transplanting only less than 1000 patients per year.
With the increasing rate of umblical cord blood (UCB) and MUD transplants, the transplant costs have increased. The government is paying, for transplants from HLAmatched unrelated in-country donors (national registries transplant registry Ankara (TRAN) and transplant registry of Istanbul (TRIS)), $ 12 000. For all the international donors, the government is supporting the full price of the donor banks. The transfer of product is still problematic. The fee for Europe is h3000 and for overseas it is h5000. There is no restriction for transplant indications in Turkey. The government has an official list of transplant centers, which are accredited by the Ministry of Health. For 10 years, many transplant candidates were referred to foreign centers for MUD or sibling allo-HCT. But this policy has now vanished because of the growing experience in the field and the rise in transplant numbers year after year.
Though the number of transplants per year is rising constantly, there are many obstacles in routine clinical applications as well. Experienced staff is the main problem in Turkey. The numbers of transplant physicians, transplant nurses and transplant technicians are decreasing owing to governmental and social policies. The technical aspects of transplant centers are also not standardized. The reimbursement policy of the social system is also very slow and discouraging. Many centers are performing transplants with less productivity. The costs are rising owing to the increasing use of supportive therapies (especially antifungals, antibiotics, antivirals, and so on). The number of transplant centers and teams is very low when compared with the population. All the transplant centers are nearly located on the west coast and in central Anatolia. There is a huge lack of transplant centers and teams in the eastern region. Almost all the transplant teams in Turkey are registered with EBMT. TTR (CIC:8405) is trying hard to convince centers to carry out on-line transplant patient registration by using the ProMISE system. In the context of the forthcoming thirty-third National Hematology Congress in Ankara, TTR and Turkish Society of Hematology (TSH) have organized a ProMISE Educational Course to help centers in on-line registration of transplant data.
Many MUD and cord blood transplants are performed from donors or cord blood units of international registries or donor banks. The national donor registries, TRIS and TRAN, have together less than 30 000 donors available. This limited number of national donors available did influence the outcome of unrelated transplants. The number of volunteer donors in registries should rise as soon as possible. The foundation of a National Donor and Cord Blood Bank under governmental support is highly recommended.
The evolution of the accreditation committee of the EBMT in 2004 showed the clear correlation between economic factors such as gross national produced (GNP) per capita and transplant rates, and team density. The comparative analysis of western with eastern European countries verified this conclusion. 7 For health-care planning and regulatory aspects, the economic strength of the country is of utmost importance.
More than 25 centers from Turkey are listed within EBMT. At the national registry TTR, nearly all the centers have given permission to share data with EBMT and TTR. A few centers are using ProMISE. Four centers are also members of Center for International Blood and Marrow Transplant Research. The health authority requires an activity survey every sixth month.
The research in transplantation and related sciences is rising year by year. The clinical research and observational papers have a lot in common. Also, a few Turkish transplant physicians are working within the EBMT and Center for International Blood and Marrow Transplant Research working parties. They are collaborating in many studies and co-authoring international registry-related papers.
In conclusion, the total HCT activity in Turkey is rising. However, if you compare the total activity to total number of population, the number of transplants both for allo and auto is below 50 tx.s per 10 000 000 population. This ratio is far below established statistics and western European countries. The transplant rate in Turkey should be targeted to the level of 400 per 10 million population within the next 10 years. To reach this goal, the number of centers, the transplant-related trained staff, the volunteer donors and cord blood units at national donor registries and cord blood banks should be increased steadily. The reimbursement policy of the government should be encouraging for supporting such a less-performed and difficult, providable, comprehensive and complicated but curing therapeutic approach.
